Navigation Links
Results of phase III study on Labopharm's novel antidepressant published in Psychiatry (Edgemont) Journal
Date:5/19/2009

sfunction in both groups.

The authors conclude that Labopharm's trazodone formulation, at the recommended daily dosage of 300 mg, appeared to be an appropriate monotherapy for patients with MDD.

Poster of Phase III Study to Appear at Scientific Meeting in Florida

Labopharm will present a poster discussing the results of the Phase III clinical trial of its novel trazodone formulation at the 49th Meeting of the New Clinical Drug Evaluation Unit (NCDEU) of the National Institute of Mental Health to be held from June 29 to July 2, 2009. The poster, entitled Once-Daily Trazodone in Major Depressive Disorder: Double-Blind, Placebo-Controlled Study, concludes Labopharm's trazodone formulation is an effective and well-tolerated treatment for MDD patients, which improves quality of sleep.

About Labopharm's Novel Antidepressant

Labopharm's novel trazodone formulation is currently under regulatory review in the United States by the Food and Drug Administration (FDA). The action date under the Prescription Drug User Fee Act (PDUFA) is July 18, 2009.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is now available in 17 countries around the world, including the U.S., Canada, the United Kingdom, France, Spain, Italy, Germany and Australia, among others. The company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For
'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. International Isotopes Inc. Announces First Quarter 2009 Financial Results
2. Encision Reports Fourth Quarter and Fiscal Year 2009 Results
3. Uroplasty to Issue Fourth Fiscal Quarter and Full Year Results on June 4, 2009
4. BMP Sunstone Reports First Quarter 2009 Financial Results
5. Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain
6. Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results
7. Jiangbo Pharmaceuticals Reports Results for the Third Quarter of its Fiscal Year 2009
8. AdCare Health Systems, Inc. Turns Profitable; Reports 2009 First Quarter Earnings Results
9. Light Sciences Oncology Announces Results of Study on Immunotherapeutic Mechanism of Aptocine(TM), a Novel Light-Activated Drug Therapy for Cancer
10. Derma Sciences Reports First Quarter 2009 Results
11. NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... Angeles, California (PRWEB) May 18, 2013 Online ... to be Rolex watch owners at a fraction ... collection of luxury timepieces in the world, buyers are urged ... As compared to buying a Rolex watch from a brick-and-mortar ... pre owned Rolex watches priced at unbelievable rates. Although ...
(Date:5/18/2013)... Dennis Thompson HealthDay Reporter , , FRIDAY, May ... unveils the latest edition of what is considered the ... its many changes continues. "This is unprecedented, the ... Jeffrey Lieberman, president-elect of the American Psychiatric Association (APA). ... what it is. You have to evaluate it and ...
(Date:5/18/2013)... a few extra cups of coffee each month might ... known as primary sclerosing cholangitis (PSC), a new study ... Minn., found that drinking coffee was associated with a ... to cirrhosis of the liver, liver failure and biliary ... relationship. "While rare, PSC has extremely detrimental ...
(Date:5/18/2013)... 2013) The use of a smartphone application ... to new research presented today at Digestive Disease ... in advance of the procedure, includes dietary restrictions ... taken at strict intervals. The better the preparation, ... cancer and precancerous polyps in the colon. The ...
(Date:5/18/2013)... -- Regular consumption of coffee is associated with ... an autoimmune liver disease, Mayo Clinic research shows. ... Disease Week 2013 conference in Orlando, Fla. ... bile ducts that results in inflammation and subsequent ... liver, liver failure and biliary cancer. , "While ...
Breaking Medicine News(10 mins):Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 2Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 3Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 2Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 3Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 4Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2Health News:New smartphone application improves colonoscopy preparation 2
... confirms that hormone replacement therapy (HRT) should not be prescribed ... help prevent chronic conditions such as heart disease . ... safe short term treatment for younger women in early menopause ... ,In 2002, the Womens Health Initiative (WHI) trial found that ...
... have, the slower you age . ,Researchers at ... moles in a study of 1,800 twins, at the Twin Research Unit ... the more likely their DNA was to have the properties to fight ... in spite of the fact that moles are linked with ...
... 13 million kilograms of antibiotics are used to raise ... are used for growth advancement and disease prevention ... up as manure, which is commonly applied to agricultural ... on manure-altered soils are exposed to antibiotics. , ...
... Thiruvananthapuram Zoo has barred the entry of visitors for a week ... reportedly lost its entire stock of Indian gaur (Bos Gaurus) -- ... the week gone by. ,It was confirmed last ... the death of animals. ,The zoo was being ...
... to a particular variety of sugar present on the surface ... are regarded as mindless killers. White blood cells (WBC) form ... our internal body. They protect our body from various kinds ... wiping out any intruder that invades the body. A new ...
... she feared that her recent miscarriage was god's way of punishing ... lost her baby when she was three months pregnant, said that ... of this year, she thought she would never recover after losing ... is all this happening?' I thought it was God's punishment for ...
Cached Medicine News:Health News:Study Confirms No HRT Benefit for Older Women 2Health News:Study Confirms No HRT Benefit for Older Women 3Health News:Dotted All Over? - Count Yourself Lucky 2Health News:Contamination of the Environment by Antibiotics Fed to Livestock 2Health News:WBC Selective About Sugar 2
(Date:5/17/2013)... -- Sanofi (EURONEXT: SAN and NYSE: SNY ) announced ... , examining the selective JAK2 inhibitor SAR302503 for myelofibrosis ... The primary endpoint assessed the proportion of patients achieving ... in previous trials, the most common adverse events were ... presented at an upcoming medical congress. ...
(Date:5/17/2013)... Mass. , May 17, 2013  Boston Scientific ... participate at the annual EuroPCR Scientific Program May 21-24 ... are pleased to present a particularly rich and diversified ... Keith Dawkins , M.D., global chief medical ... trials will be presented, including the NG PROMUS trial, ...
(Date:5/16/2013)... 16, 2013  PTC Therapeutics, Inc., today announced that ... with the U.S. Securities and Exchange Commission ("SEC") relating ... stock. The number of shares to be offered and ... determined. (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) ... joint book-running managers for the offering. Cowen and Company ...
Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
... Conn. , May 14 Zargis Medical Corp., ... today announced that its Zargis Cardioscan device and the compatible ... of a Gold Award on April 29th at ... Channel in New York City . The prestigious Gold ...
... , Germany , May 14, 2010 On ... international user meeting of endoscopic,spinal surgery in Veenhuizen/Niederlande. Besides the ten ... Europe , the United States ,and other countries are expected ... will be opened with a keynote lecture of,Prof. Dr. Gerbrand ...
Cached Medicine Technology:Zargis Medical Strikes Gold at 2010 Edison Awards 2joimax(R) Holds the First International TESSYS(R) User Meeting in Veenhuizen, The Netherlands, and Announces the Launch of Various New Products for Endoscopic Spinal Surgery 2
... fully threaded 2.4 mm diameter titanium suture anchor. ... using either a powered handpiece or manually with ... implant is ideal for Bankart and SLAP repairs ... very high pull-out strengths. FASTak anchors are available ...
... The Bio-Corkscrew FT (fully threaded) is a ... to be inserted flush with the cortical ... anchor stability. The fully threaded design substantially ... with protruding eyelets. The fully threaded design ...
... is a 3 mm x 14 mm bioabsorbable ... the shoulder, knee, elbow and ankle. The exclusive ... body of the anchor and provides superior resistance ... This unique eyelet design allows the attached suture ...
... Suture Kit is available for ... procedures. This kit contains a ... three different colored versions of ... differentiation, large cutting Spring Eye ...
Medicine Products: